PO.BCS01.03 · 生物信息与计算

单细胞多组学测序揭示与髓母细胞瘤中ecDNA扩增相关的独特转录程序

Single-cell multiome sequencing reveals distinct transcriptional programs associated with ecDNA amplifications in medulloblastoma

海报缩略图:单细胞多组学测序揭示与髓母细胞瘤中ecDNA扩增相关的独特转录程序
编号 2689 展板 14 时间 4/20 02:00–05:00 区域 Section 1 主讲 Ashley Hui, BS;MS
分会场 Application of Bioinformatics to Cancer Biology 3
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Hui Hui1, Yan Yuen Lo2, Jessica Wang2, Rishaan Kenkre3, Jon D. Larson2, Sunita Sridhar4, Owen Chapman5, Lukas Chavez6

1Sanford Burnham Prebys Med. Discovery Inst., La Jolla, CA,2Sanford Burnham Prebys Medical Discovery Institute, San Diego, CA,3Sanford Childrens Health Research Center, San Diego, CA,4Rady Children's Hospital, San Diego, CA,5Nagoya City University, Nagoya, Japan,6Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA

摘要 Abstract

中文摘要
染色体外DNA(ecDNA)是肿瘤内异质性的关键驱动因素,并与治疗耐药和不良患者预后相关。然而,在单细胞水平识别、分离和分析ecDNA的技术局限性阻碍了我们对其在肿瘤发生和治疗应答中作用的理解。我们此前开发了一种单细胞多组学(RNA + ATAC)测序方法,能够同时分析ecDNA及其基因表达谱。该方法在音猬因子(sonic hedgehog)亚组的一例髓母细胞瘤肿瘤中的初步应用揭示了ecDNA阳性细胞与ecDNA阴性细胞及非恶性细胞相比具有独特的转录特征。基于这些发现,我们在另一队列的携带ecDNA扩增的髓母细胞瘤标本中进行了多组学单细胞测序。初步分析揭示了ecDNA阳性和ecDNA阴性肿瘤细胞之间不同的功能特征。例如,ecDNA阳性肿瘤细胞显示DNA复制、重组和损伤修复通路上调,而ecDNA阴性细胞则表现出突触活性、细胞信号传导和形态发生通路的表达增加。我们正在进行的分析侧重于进一步定义区分ecDNA阳性与ecDNA阴性肿瘤细胞的转录程序,最终为未来针对ecDNA驱动的髓母细胞瘤肿瘤中转录依赖性的功能遗传学和药理学研究提供指导。
查看英文原文 English abstract
Extrachromosomal DNA (ecDNA) is a key driver of intratumoral heterogeneity and has been linked to therapeutic resistance and poor patient outcomes. However, technical limitations in identifying, isolating, and analyzing ecDNA at the single-cell level have hindered our understanding of its role in tumor development and treatment response. We have previously developed a single-cell multiome(RNA + ATAC) sequencing approach that enables the simultaneous analyses of ecDNA and its gene expression profiles. Initial application of this method in a medulloblastoma tumor of the sonic hedgehog subgroup revealed distinct transcriptional signatures in ecDNA-positive compared to ecDNA-negative and non-malignant cells. Building on these findings, we performed multiome single-cell sequencing in an additional cohort of medulloblastoma specimens harboring ecDNA amplifications. Initial analyses revealed distinct functional characteristics between ecDNA-positive and ecDNA-negative tumor cells. For example, ecDNA-positive tumor cells show up-regulation of DNA replication, recombination, and damage repair pathways, while ecDNA-negative cells demonstrated increased expression of synaptic activity, cell signaling, and morphogenesis pathways. Our ongoing analysis focuses on further defining the transcriptional programs that distinguish ecDNA-positive from ecDNA-negative tumor cells, ultimately informing future functional genetic and pharmacological studies targeting transcriptional dependencies in ecDNA-driven medulloblastoma tumors.
利益披露 Disclosure
H. Hui, None.

← 返回 AACR 2026 检索